A new point mutation (P157S) in the reverse transcriptase of human immunodeficiency virus type 1 confers low-level resistance to (-)-beta-2',3'-dideoxy-3'-thiacytidine.
A new point mutation (P157S) in the reverse transcriptase of human immunodeficiency virus type 1 confers low-level resistance to (-)-beta-2',3'-dideoxy-3'-thiacytidine.
复制标题
1 型人类免疫缺陷病毒逆转录酶中的新点突变 (P157S) 赋予对 (-)-β-2,3-双脱氧-3-硫胞苷的低水平耐药性。
DOI：
10.1128/aac.43.8.2077
复制
发表时间：
1999
影响因子：
4.9
通讯作者：
North,TW
中科院分区：
文献类型：
--
作者：
Smith,RA;Klarmann,GJ;Stray,KM;vonSchwedler,UK;Schinazi,RF;Preston,BD;North,TW
A P157S mutation in the reverse transcriptase (RT) of human immunodeficiency virus type 1 conferred fivefold resistance to (−)-β-2′,3′-dideoxy-3′-thiacytidine in cell culture. Interestingly, the P157S mutation resulted in increased sensitivity (two- to threefold) to 3′-azido-3′-deoxythymidine (AZT) and to (R)-9-(2-phosphonylmethoxypropyl)adenine (PMPA). A similar increase in susceptibility to AZT and to PMPA was also conferred by the M184V mutation in RT.
